OncoMatch/Clinical Trials/NCT06664411
Pola-ZR2P in Previously Untreated DLBCL
Is NCT06664411 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy for diffuse large b-cell lymphoma.
Treatment: Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy — The goal of this phase 2 trial is to test the safety and efficacy of Pola-ZR2P as induction therapy in patients with DLBCL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Demographics
Prior therapy
Cannot have received: chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06664411 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify